Lexeo Therapeutics’ LX2020 Gains RMAT Designation

Company: Lexeo Therapeutics · Event Type: Regulatory Designation · Modality: Systemic AAVrh10 Gene Therapy · Asset: LX2020 · Indication: PKP2-Associated Arrhythmogenic Cardiomyopathy Summary FDA granted Regenerative Medicine Advanced Therapy designation to LX2020, Lexeo Therapeutics’ systemic AAVrh10 gene therapy for plakophilin-2-associated arrhythmogenic cardiomyopathy. The designation was…